Table 3.
Clinicopathological characteristics of patients with early BCR and non-early BCR.
| Variables | Early BCR (n = 36) |
Non-Early BCR (n = 634) |
p Value |
|---|---|---|---|
| Age (years), mean (SD) | 68.5 (6.3) | 68.1 (7.0) | 0.69 |
| PSA level (ng/mL), median (IQR) | 18.6 (10.8–42.5) | 12.5 (7.1–24.1) | 0.01 |
| cT stage | cT1: 4 cT2a: 5, cT2b: 5, cT2c: 2 cT3a: 10, cT3b: 10 |
cT1: 106 cT2a: 127, cT2b: 86, cT2c: 35 cT3a: 229, cT3b: 51 |
0.03 |
| Gleason score | 3 + 4: 4, 4 + 3: 6 4 + 4: 4, 3 + 5: 2 |
3 + 3: 22 3 + 4: 89, 4 + 3: 97 4 + 4: 131, 3 + 5: 23 5 + 5: 3 |
0.52 |
| %PC (%), median (IQR) | 50.0 (35.1–83.3) | 40.0 (25.0–27.0) | <0.01 |
| ADT duration (months), median (IQR) | 24.9 (23.7–29.1) | 25.0 (24.0–27.0) | 0.48 |
| STAMPEDE high-risk (%) | 16 (44.4%) | 168 (25.9%) | 0.02 |
ADT: androgen deprivation therapy, BCR: biochemical recurrence, IQR: interquartile range, %PC: percentage of positive biopsy cores, PSA: prostate-specific antigen, SD: standard deviation, STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate cancer.